ARTICLE | Clinical News
SRX-1177 regulatory update
May 18, 2015 7:00 AM UTC
FDA granted Orphan Drug designation to SRX-1177 to treat stage IIB-IV malignant melanoma. SRX-1177 is in preclinical testing. The radiolabeled peptide binds to melanocortin 1 receptors ( MC1R) to iden...